Standardized application of poly ADP-ribose polymerase inhibitors in maintenance therapy of ovarian cancer / 中国医师杂志
Journal of Chinese Physician
;
(12): 1918-1920,F3, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-932014
ABSTRACT
Ovarian cancer is a common gynecological malignancy and the most common cause of cancer death. Ovarian cancer is usually treated with surgery combined with chemotherapy as the preferred treatment. In recent years, with the continuous development of medical technology and the in-depth research on ovarian cancer at home and abroad, the molecular targeted therapy of ovarian cancer has received extensive attention. Among them, the poly ADP-ribose polymerase (PARP) inhibitors have made great breakthroughs and advances in the precise and standardized treatment of ovarian cancer. This paper discusses the study of PARP inhibitors in sensitivity biomarkers of ovarian cancer, and reviews the standardized treatment of PARP inhibitors in maintenance therapy of ovarian cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Chinese Physician
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS